百克生物发预亏，预计2025年度归母净亏损2.2亿元到2.8亿元

Core Viewpoint - The company, Baike Biotechnology (688276.SH), expects to report a net profit loss attributable to shareholders of the parent company ranging from 220 million to 280 million yuan for the year 2025, indicating a significant decline compared to the previous year [1] Group 1: Financial Performance - The anticipated net profit loss for 2025 represents a decrease of 452 million to 512 million yuan compared to the same period last year [1] - The year-on-year decline in net profit is projected to be between 194.79% and 220.64% [1] Group 2: Industry Challenges - The company faces multiple challenges in its operating environment, including intensified industry competition, insufficient public willingness to get vaccinated, and a declining birth rate [1]